Minghui Pharmaceutical has just closed a $131 million “pre-IPO” financing round to fuel its dual ambitions in dermatology and oncology. The funds will accelerate the planned Chinese launch of MH004, a once-daily, pan-JAK inhibitor cream poised to transform treatment for inflammatory skin conditions, while also propelling several clinical-stage antibody programs against hard-to-treat cancers.

MH004: A new cream for stubborn dermatitis

• What it is: MH004 is a small-molecule Janus kinase (JAK) inhibitor formulated as a topical cream. By blocking JAK enzymes, key drivers of inflammation, the cream soothes conditions like atopic dermatitis without the systemic side effects of oral treatments.

• Clinical progress: After a successful Phase 2 trial in 2023 demonstrating significant itch and rash reduction, Minghui filed for regulatory approval in China. The Phase 3 readout results are expected later this year, with MH004’s launch slated for early 2026 if approved.

Bi-specific and ADC cancer programs

• MHB039A + MHB036C combo: Minghui’s PD-1/VEGF bispecific antibody (MHB039A) and its TROP-2-targeted antibody-drug conjugate (MHB036C) entered a Phase 2 study in advanced non-small cell lung cancer (NSCLC) in May. By simultaneously blocking the PD-1 immune checkpoint and inhibiting tumor blood-vessel growth, the duo aims to deliver one-two punches against NSCLC.

• B7-H3 ADC (MHB088C): This ADC, designed to zero in on the B7-H3 protein found on many solid tumors, is currently in trials for small cell lung cancer and metastatic castration-resistant prostate cancer. In May, Minghui out-licensed China rights to Qilu Pharmaceutical for 280 million CNY (≈$38 million), underlining the program’s commercial promise.

Market opportunity & strategic growth

• Dermatology: China’s eczema and psoriasis market is projected to exceed $3 billion by 2027, driven by increasing prevalence and demand for safer, targeted therapies. A topical JAK cream could capture a significant share, especially among patients seeking alternatives to steroids and biologics.

• Oncology: The global antibody-drug conjugate (ADC) market reached $3.5 billion in 2024 and is expected to double by 2028, as physicians embrace precision payload delivery. Meanwhile, bispecific antibodies are among the hottest areas in immuno-oncology, with multiple approvals and blockbuster sales in the pipeline.

Minghui’s next chapter
“This financing marks an important milestone as we continue to advance a globally competitive pipeline and enter our next stage of growth,” said Minghui CEO Dr. Guoqing Cao. With the new capital, Minghui plans to:

1. Complete MH004’s Phase 3 readout and prepare for a commercial rollout in China.

2. Scale up GMP manufacturing for its leading antibody candidates.

3. Expand clinical development into additional tumor types and geographic regions.

As Minghui moves toward its IPO, the Shanghai biotech stands out by tackling both widespread inflammatory diseases and the toughest cancer challenges. If MH004 succeeds in China’s large dermatology market, and its antibody programs follow suit abroad, Minghui could emerge as a rising star in global biopharma.